Deciphera Pharmaceuticals - DCPH Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $19.44
Forecasted Upside: 5.11 %
Number of Analysts: 11
Breakdown:
2 Sell Ratings
4 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$18.50 As of 09/30/2022 01:00 AM ET

▲ +0.88 (4.99%)

1 month | 3 months | 12 months

Get New Deciphera Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCPH

^$19.44

▲ +5.11% Upside Potential

This price target is based on 11 analysts offering 12 month price targets for Deciphera Pharmaceuticals in the last 3 months. The average price target is $19.44, with a high forecast of $25.00 and a low forecast of $6.00. The average price target represents a 5.11% upside from the last price of $18.50.

Current Consensus is Hold

The current consensus among 11 polled investment analysts is to hold stock in Deciphera Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
5 hold ratings
1 sell ratings

Ratings as of

4/10/2021

0 strong buy ratings
3 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

7/9/2021

0 strong buy ratings
4 buy ratings
3 hold ratings
1 sell ratings

Ratings as of

10/7/2021

0 strong buy ratings
4 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

1/5/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

4/5/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

7/4/2022

0 strong buy ratings
5 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

9/2/2022

0 strong buy ratings
5 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

10/2/2022

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/27/2022	Stifel Nicolaus	Boost Target	Hold	$11.00 ➝ $18.00	Low
9/12/2022	SVB Leerink	Boost Target	Outperform	$21.00 ➝ $25.00	Low
9/12/2022	HC Wainwright	Boost Target	Buy	$20.00 ➝ $25.00	Low
9/11/2022	Piper Sandler	Boost Target		$13.00 ➝ $18.00	Low
8/29/2022	Cowen	Initiated Coverage	Outperform	$25.00	Low
8/29/2022	Cowen	Initiated Coverage	Outperform	$25.00	Low
8/5/2022	SVB Leerink	Boost Target	Outperform	$15.00 ➝ $21.00	Low
8/5/2022	HC Wainwright	Boost Target	Buy	$15.00 ➝ $20.00	Low
8/5/2022	JMP Securities	Upgrade	Market Perform ➝ Outperform	$23.00	Low
2/28/2022	Barclays	Downgrade	Equal Weight ➝ Underweight	$11.00 ➝ $6.00	Low
12/1/2021	HC Wainwright	Lower Target	Buy	$25.00 ➝ $15.00	High
11/30/2021	Piper Sandler	Lower Target	Neutral	$14.00 ➝ $11.00	High
11/22/2021	Jonestrading	Reiterated Rating	Sell		High
11/15/2021	SVB Leerink	Reiterated Rating	Buy	$70.00	Medium
11/8/2021	HC Wainwright	Lower Target	Buy	$70.00 ➝ $25.00	High
11/8/2021	Barclays	Downgrade	Overweight ➝ Equal Weight	$50.00 ➝ $11.00	High
11/7/2021	Stifel Nicolaus	Downgrade	Buy ➝ Hold	$60.00 ➝ $10.00	High
11/5/2021	Piper Sandler	Downgrade	Overweight ➝ Neutral		N/A
11/5/2021	Guggenheim	Downgrade	Buy ➝ Neutral		N/A
11/5/2021	Truist Financial	Downgrade	Buy ➝ Hold	$65.00 ➝ $10.00	N/A
11/5/2021	JMP Securities	Lower Target	Market Outperform	$70.00 ➝ $64.00	N/A
10/4/2021	Truist Financial	Lower Target	Buy	$84.00 ➝ $65.00	Medium
9/29/2021	Stifel Nicolaus	Initiated Coverage	Buy		Low
9/20/2021	HC Wainwright	Reiterated Rating	Buy	$70.00	Low
9/20/2021	JMP Securities	Reiterated Rating	Buy	$70.00	Low
8/4/2021	HC Wainwright	Lower Target	Positive ➝ Buy	$75.00 ➝ $70.00	High
5/5/2021	HC Wainwright	Lower Target	Buy	$80.00 ➝ $75.00	High
5/5/2021	Barclays	Lower Target	Overweight	$70.00 ➝ $65.00	High
5/5/2021	Piper Sandler	Lower Target	Overweight	$75.00 ➝ $60.00	High
3/30/2021	Credit Suisse Group	Initiated Coverage	Outperform	$78.00	High
2/10/2021	Barclays	Lower Target	Overweight	$85.00 ➝ $70.00	Low
2/10/2021	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$70.00	Low
12/2/2020	Stifel Nicolaus	Initiated Coverage	Buy	$75.00	Medium
11/12/2020	SVB Leerink	Boost Target	Market Perform	$58.00 ➝ $70.00	Low
9/14/2020	SVB Leerink	Boost Target	Market Perform	$54.00 ➝ $58.00	Medium
9/14/2020	JPMorgan Chase & Co.	Initiated Coverage	Neutral		High
8/5/2020	SVB Leerink	Lower Target	Market Perform	$55.00 ➝ $54.00	Low
6/12/2020	Guggenheim	Reiterated Rating	Buy	$70.00	High
5/18/2020	SunTrust Banks	Boost Target	Buy	$82.00 ➝ $91.00	Medium
5/18/2020	Barclays	Reiterated Rating	Buy	$80.00 ➝ $85.00	Medium
5/7/2020	Nomura Instinet	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low
5/6/2020	Nomura	Downgrade	Buy ➝ Neutral	$84.00 ➝ $60.00	Low
5/6/2020	JPMorgan Chase & Co.	Lower Target	Overweight	$50.00 ➝ $49.00	High
5/6/2020	HC Wainwright	Boost Target	Buy	$60.00 ➝ $80.00	High
4/29/2020	SunTrust Banks	Boost Target	Buy	$77.00 ➝ $82.00	Medium
4/29/2020	SVB Leerink	Boost Target	Hold	$50.00 ➝ $55.00	Medium
3/4/2020	Barclays	Initiated Coverage	Overweight	$70.00	High
1/22/2020	Piper Sandler	Reiterated Rating	Buy	$75.00	Low
1/21/2020	Nomura Securities	Boost Target	Buy	$57.00 ➝ $84.00	Low
1/15/2020	JMP Securities	Reiterated Rating	Buy	$70.00	Low
1/10/2020	SunTrust Banks	Initiated Coverage	Buy	$77.00	Low
12/20/2019	Piper Jaffray Companies	Boost Target	Overweight	$55.00 ➝ $75.00	Low
12/20/2019	Jefferies Financial Group	Boost Target	Buy	$53.00 ➝ $77.00	Medium
11/5/2019	JMP Securities	Boost Target	Outperform ➝ Market Outperform	$45.00 ➝ $54.00	Low
10/29/2019	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$29.00 ➝ $34.00	Medium
10/22/2019	JMP Securities	Initiated Coverage	Outperform		Low
10/3/2019	HC Wainwright	Initiated Coverage	Buy	$60.00	High
9/30/2019	Piper Jaffray Companies	Set Target	Buy	$55.00	High
9/30/2019	Jefferies Financial Group	Initiated Coverage	Buy	$47.00	High
8/14/2019	SunTrust Banks	Boost Target	Positive ➝ Buy	$60.00	Low
8/14/2019	SVB Leerink	Reiterated Rating	Underperform ➝ Positive	$20.00 ➝ $29.00	High
8/14/2019	Cantor Fitzgerald	Boost Target	Overweight	$43.00 ➝ $55.00	High
8/13/2019	Guggenheim	Boost Target	Buy	$44.00 ➝ $66.00	High
7/18/2019	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy	$42.00	Low
6/3/2019	Piper Jaffray Companies	Boost Target	Overweight	$50.00 ➝ $55.00	High
1/1/2019	B. Riley	Downgrade	Buy ➝ Neutral		High
12/31/2018	B. Riley	Initiated Coverage	Neutral ➝ Buy	$27.00 ➝ $34.00	High
12/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium
11/16/2018	SVB Leerink	Lower Target	Underperform	$28.00 ➝ $20.00	Medium
10/3/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$53.00	Medium
9/24/2018	SVB Leerink	Initiated Coverage	Underperform ➝ Underperform	$28.00	Low
9/17/2018	Guggenheim	Initiated Coverage	Buy		High
9/6/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$53.00	High
8/29/2018	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$47.00	Medium
8/22/2018	Cantor Fitzgerald	Initiated Coverage	Overweight	$53.00	Medium
7/5/2018	SunTrust Banks	Initiated Coverage	Buy		High
6/19/2018	JMP Securities	Boost Target	Outperform	$65.00	Low
6/19/2018	B. Riley	Downgrade	Buy ➝ Neutral	$43.00	Medium
6/12/2018	Piper Jaffray Companies	Boost Target	Overweight	$50.00	Low
6/4/2018	JPMorgan Chase & Co.	Boost Target	Overweight ➝ Overweight	$30.00 ➝ $33.00	High
5/9/2018	B. Riley	Lower Target	Buy ➝ Buy	$52.00 ➝ $43.00	High
2/16/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$43.00	High
10/23/2017	Nomura Securities	Initiated Coverage	Buy ➝ Buy	$57.00	N/A
10/23/2017	Piper Jaffray Companies	Initiated Coverage	Overweight ➝ Overweight	$35.00	N/A
10/23/2017	Nomura Instinet	Initiated Coverage	Buy	$57.00	N/A
10/23/2017	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Outperform	$38.00	N/A
10/23/2017	JPMorgan Chase & Co.	Initiated Coverage	Overweight ➝ Overweight	$30.00	N/A

(Data available from 10/2/2017 forward)

News Sentiment Rating

0.47 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/6/2022

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/5/2022

4 very positive mentions
5 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

5/5/2022

1 very positive mentions
3 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

6/4/2022

1 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/4/2022

1 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/3/2022

2 very positive mentions
7 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

9/2/2022

4 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

10/2/2022

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $18.50

$17.43

$19.31

50 Day Range

MA: $16.44

$12.38

$20.23

52 Week Range

Now: $18.50

$6.51

$20.88

Volume

1,399,518 shs

Average Volume

950,184 shs

Market Capitalization

$1.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?: The following Wall Street research analysts have issued reports on Deciphera Pharmaceuticals in the last year: Barclays PLC, Cowen Inc, Cowen Inc., Guggenheim, HC Wainwright, JMP Securities, Jonestrading, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, and Truist Financial Co..
View the latest analyst ratings for DCPH.
What is the current price target for Deciphera Pharmaceuticals?: 9 Wall Street analysts have set twelve-month price targets for Deciphera Pharmaceuticals in the last year. Their average twelve-month price target is $19.44, suggesting a possible upside of 5.1%. Cowen Inc. has the highest price target set, predicting DCPH will reach $25.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $6.00 for Deciphera Pharmaceuticals in the next year.
View the latest price targets for DCPH.
What is the current consensus analyst rating for Deciphera Pharmaceuticals?: Deciphera Pharmaceuticals currently has 2 sell ratings, 4 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in DCPH, but not buy more shares or sell existing shares.
View the latest ratings for DCPH.
What other companies compete with Deciphera Pharmaceuticals?: Other companies that are similar to Deciphera Pharmaceuticals include Avid Bioservices, Zentalis Pharmaceuticals, FibroGen, Madrigal Pharmaceuticals and Gossamer Bio. Learn More about companies similar to Deciphera Pharmaceuticals.
How do I contact Deciphera Pharmaceuticals' investor relations team?: Deciphera Pharmaceuticals' physical mailing address is 200 SMITH STREET, Waltham MA, 02451. The company's listed phone number is (781) 209-6400 and its investor relations email address is [email protected] The official website for Deciphera Pharmaceuticals is www.deciphera.com. Learn More about contacing Deciphera Pharmaceuticals investor relations.

Deciphera Pharmaceuticals - DCPH Stock Price Target and Predictions

Analyst Price Target for DCPH

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.47 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Deciphera Pharmaceuticals?

What is the current price target for Deciphera Pharmaceuticals?

What is the current consensus analyst rating for Deciphera Pharmaceuticals?

What other companies compete with Deciphera Pharmaceuticals?

How do I contact Deciphera Pharmaceuticals' investor relations team?